Table 1.

Characteristics of AML patients whose samples were used in this study

Patient no.	Blasts, %	Source	Cytogenetics	Treatments and responses at sampling
1	92	Apheresis	Diploid female karyotype 46,XX[20]	New diagnosis
2	92	PB	45,XY,t(1;12)(p34.3;q24.1),-7[20]	CR on IDA+ara-C then relapsed; relapsed on high-dose ara-C consolidation, transplant, and reinduction IDA+ara-C; and resistant to DAC+gemtuzumab ozogamicin
3	85	PB	Diploid female karyotype 46,XX[30]	CR on IDA+high-dose ara-C then relapsed; CR on infusion then relapsed;resistant to 5-AZA+ara-C and CP-4055
4	98	PB	Diploid female karyotype 46,XX[20]	CR on IDA+ara-C then relapsed; consolidated with high dose ara-C;resistant to mitoxantrone+VP-16 and CP-4055
5	71	PB	46,XX,t(8;21)(q22;q22)[2],46,sl,-X, t(8;21)(q22;q22)[4],47,sl,X,+18,+der(21)t(8;21)(q22;q22)[4],sl,del(15)(q11.2q15),+18,add(20)(q11.2), +der(21)t(8;21)(q22;q22)[cp10] etc	CRp on bid FA+gemtuzumab ozogamicin then relapsed; resistant to oxyliplatin+FA
6	56	PB	Diploid male karyotype 46,XY[20]	Initial blast reduction, then increased on bortezomib+melphalan; resistant to 5-AZA+AC; stable disease and a gradual reduction of marrow blast on SAHA+DAC; resistant to Arry-520

AML indicates acute myeloid leukemia; PB, peripheral blood; CR, complete response; bid, twice daily; DAC, dacitabine; VP-16, etoposide; FA, fludarabine; 5-AZA+AC, 5-azacitidine + ara-c; and SAHA, suberoylanilide hydroyxamic acid.